Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR5153)
Name
Spironolactone
Synonyms
spironolactone; 52-01-7; Aldactone; Spirolactone; Verospiron; Euteberol; Spirolang; Verospirone; Spiroctan; Acelat; Aldactone A; Spironocompren; Melarcon; Spiresis; Spiridon; Uractone; Urusonin; Alderon; Spirone; Xenalon; Dira; Spiro-Tablinen; Spironolactone A; spironolattone; Aquareduct; Aldopur; Espironolactona; Spironolactonum; Aldace; Almatol; Deverol; Altex; Berlactone; SC 9420; SC-9420; UNII-27O7W4T232; MFCD00082250; CHEMBL1393; C24H32O4S; CHEBI:9241; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); Spironolattone [DCIT]; 27O7W4T232; NSC-150399; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate; Spironolactone, 99%; Aldactide; Spiractin; Spironolactonum [INN-Latin]; Espironolactona [INN-Spanish]; DSSTox_CID_14186; DSSTox_RID_79120; DSSTox_GSID_34186; SC 15983; (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan]-6'-ene-5,5'-dione; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate; Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Diatense; Aldactone (TN); 17-Hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid-gamma-lactone-7-acetate; SMR000471892; HSDB 3184; EINECS 200-133-6; NSC 150399; BRN 0057767; spirotone; Spiranolactone; Carospir; 2oax; 3vhu; CAS-52-01-7; NCGC00015948-02; 3-(3-Keto-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid lactone; 7-.alpha.-(acetylthio)-17-.alpha.-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, .gamma.-lactone; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; S-((7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl) ethanethioate; Spironolactone [USP:INN:BAN:JAN]; Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, gamma-lactone, (7alpha,17alpha)-; Prestwick0_000128; Prestwick1_000128; Prestwick2_000128; Prestwick3_000128; 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone acetate; 3'-(3-Oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propionic acid lactone; 3-(3-Keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic acid lactone; BIDD:PXR0071; SCHEMBL20939; BSPBio_000176; 17alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate; 4-18-00-01601 (Beilstein Handbook Reference); MLS001074672; MLS001333253; MLS001333254; MLS002153245; MLS002207058; MLS002548846; SPBio_002115; BPBio1_000194; GTPL2875; DTXSID6034186; Spironolactone (JP17/USP/INN); HMS1568I18; HMS2090N21; HMS2095I18; HMS2236E06; HMS3259G11; HMS3712I18; ACT02596; AMY40521; HY-B0561; Spironolactone, 97.0-103.0%; ZINC3861599; Tox21_113047; Tox21_302154; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; BDBM50228080; NSC150399; s4054; 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; AKOS015896401; AC-4214; CCG-220128; DB00421; KS-5234; MCULE-4394091100; NC00482; NCGC00164397-01; NCGC00164397-02; NCGC00164397-03; NCGC00164397-05; NCGC00255229-01; 17-alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-alpha-mercapto-3-oxo-, gamma-lactone acetate; AK546740; CPD000471892; H490; Spironolactone 1.0 mg/ml in Acetonitrile; AB00513806; S0260; 7080-EP2269989A1; 7080-EP2270011A1; 7080-EP2272841A1; 7080-EP2295406A1; 7080-EP2298772A1; 7080-EP2298776A1; 7080-EP2301936A1; 7080-EP2308562A2; 7080-EP2308839A1; C07310; D00443; AB01275520-01; AB01275520_02; 082S250; Q422188; SR-01000765419; SR-05000000452; Q-201737; SR-01000765419-2; SR-05000000452-2; BRD-K90027355-001-03-4; BRD-K90027355-001-19-0; Z1551900341; Spironolactone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone acetate; Spironolactone, United States Pharmacopeia (USP) Reference Standard; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, acetate; Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, (7.alpha.,17.alpha.)-; (7?,17?)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid ?-lactone; 7alpha-(Acetylthio)-17alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid gamma-lactone; Spironolactone for system suitability, European Pharmacopoeia (EP) Reference Standard; 17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21- CARBOXYLIC ACID; GAMMA-LACTONE ACETATE; 2'',15''-dimethyl-5,5''-dioxo-(9''R)-spiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate(Spiranolactone); 7-alpha-(acetylthio)-17-alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, gamma-lactone (9CI); S-(2''R,7R,8R,9S,10R,13S,14S)-10,13-dimethyl-3,5''-dioxo-1,2,3,4'',5'',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3''H-spiro[cyclopenta[a]phenanthrene-17,2''-furan]-7-yl ethanethioate
    Click to Show/Hide
Molecular Type
Small molecule
Disease Heart failure [ICD-11: BD10] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C24H32O4S
PubChem CID
5833
Canonical SMILES
CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C
InChI
1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChIKey
LXMSZDCAJNLERA-ZHYRCANASA-N
CAS Number
CAS 52-01-7
ChEBI ID
CHEBI:9241
TTD Drug ID
D0EP0C
DrugBank ID
DB00421
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vitamin D      Saccharomyces cerevisiae     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression CCL2  Molecule Info 
Pathway MAP
Down-regulation Expression IL1A  Molecule Info 
Pathway MAP
Down-regulation Expression IL1B  Molecule Info 
Pathway MAP
Down-regulation Expression MMP-9  Molecule Info 
Pathway MAP
Down-regulation Expression NOS2  Molecule Info 
Pathway MAP
                    Biological
                    Regulation
Increase M2/M1 ratio
                    In-vitro Model RAW-Dual CVCL_A7ZK Mouse leukemia Mus musculus
                    In-vivo Model Six- to eight-week-old C57BL/6J female mice were used in this study.
                    Experimental
                    Result(s)
VD3 and SP may constitute an effective treatment regimen to improve wound healing after NM or other skin chemical injury.
Target and Pathway
Target(s) Mineralocorticoid receptor (MR)  Molecule Info  [3]
KEGG Pathway Aldosterone-regulated sodium reabsorption Click to Show/Hide
Pathwhiz Pathway Kidney Function Click to Show/Hide
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875).
Reference 2 A novel treatment for skin repair using a combination of spironolactone and vitamin D3. Ann N Y Acad Sci. 2020 Nov;1480(1):170-182.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China